CHEST Guidelines-Survival-Improved-in-Patients-Aged ≤-7

Survival-Improved-in-Patients-Aged ≤-7

Pdf Summary

The study analyzes survival trends in patients aged 70 years and older with systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH) in France from 2006 to 2017. The aim was to observe changes in survival rates over two six-year periods, 2006-2011 and 2012-2017, utilizing data from the French Pulmonary Hypertension Network and the French National Systemic Sclerosis Cohort.<br /><br />The study included 306 patients, split between 2006-2011 (167 patients) and 2012-2017 (139 patients). The analysis showed no significant difference in overall survival between these two periods; however, a significant interaction between the period of diagnosis and age was noted. Specifically, patients aged 70 years or younger saw improved survival rates in the later period, not observed in older patients.<br /><br />The improvement in survival among the younger cohort (70 years and younger) could be partly attributed to the more frequent use of dual combination therapies, such as endothelin receptor antagonists combined with phosphodiesterase type 5 inhibitors, which were more regularly prescribed in the 2012-2017 period. Conversely, no significant change in the initial treatment strategies was observed in patients older than 70 years between the two periods.<br /><br />The study concludes that survival has improved over time for younger SSc-PAH patients in France during this timeframe, likely due to advancements in treatment protocols and possibly better disease management strategies. The research suggests that age-specific therapeutic strategies might influence outcomes and calls for further investigation to understand the reasons behind these survival trends. The study also highlights the significant role that improved medical care and management may play in these observed trends.

Keywords

systemic sclerosis-associated pulmonary arterial hypertension

SSc-PAH

survival trends

French Pulmonary Hypertension Network

French National Systemic Sclerosis Cohort

dual combination therapies

endothelin receptor antagonists

phosphodiesterase type 5 inhibitors

age-specific therapeutic strategies

treatment protocols